[New data on monoamine oxidase inhibitors].
D000166:Acridines / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000201:enzymology; D003593:Cytoplasm / Q000201:enzymology; D006834:Hydrazines / Q000494:pharmacology; D007490:Iproniazid / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D008099:Liver / Q000201:enzymology; D008566:Membranes / Q000201:enzymology; D008928:Mitochondria / Q000201:enzymology; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010069:Oxadiazoles / Q000494:pharmacology; D010293:Pargyline / Q000494:pharmacology; D010300:Parkinson Disease / Q000188:drug therapy; D011725:Pyridines / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D011832:Radiation Injuries / Q000188:drug therapy; D051381:Rats; D014191:Tranylcypromine / Q000494:pharmacology; D014807:Vitamin D / Q000009:adverse effects
D000166:Acridines; D006834:Hydrazines; D007546:Isoquinolines; D008996:Monoamine Oxidase Inhibitors; D010069:Oxadiazoles; D011725:Pyridines; D011758:Pyrroles; D014807:Vitamin D; D014191:Tranylcypromine; D010293:Pargyline; D007490:Iproniazid
Novye dannye ob ingibitorakh monoaminoksidazy.